Metraipolis › archive › dc_e8602f9db384

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis — Europe PMC PMID:42563503

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42563503
DOI
10.1111/1759-7714.70362
License (as archived)
solo-consultazione
Archived
2026-10-06T18:59:33.657Z
SHA-256 of the archived text
7abce6d9a40c6b1bf35b98d071f58f6881ee602ec51ebc0294efd5d2b185c3b0
Stable URL of this page
https://metraipolis.com/documento/dc_e8602f9db384

How to cite

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis — Europe PMC PMID:42563503 — Europe PMC (en), https://europepmc.org/article/MED/42563503 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e8602f9db384 (Metraipolis archive dc_e8602f9db384, sha256 7abce6d9a40c6b1bf35b98d071f58f6881ee602ec51ebc0294efd5d2b185c3b0)
BibTeX
@misc{dce8602f9db384,
  title = {Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis — Europe PMC PMID:42563503},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42563503},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e8602f9db384; sha256 7abce6d9a40c6b1bf35b98d071f58f6881ee602ec51ebc0294efd5d2b185c3b0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42563503. Agents can read the archived copy with the MCP tool read_document.